Novanta Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing also reports fourth-quarter results. Novanta supplies photonics, vision and precision-motion components and subsystems, primarily to medical and advanced-industrial OEMs.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $590.6 million | $626.1 million |
| Gross profit / margin | $244.5 million / 41.4% | $262.1 million / 41.9% |
| Operating income / margin | $55.9 million / 9.5% | $55.3 million / 8.8% |
| Net income | $44.5 million | $40.8 million |
| Diluted EPS | $1.25 | $1.15 |
| Cash from operating activities | $140.2 million | $63.2 million |
| Capital expenditures | $10.5 million | $10.7 million |
| Cash and cash equivalents at year-end | $125.1 million | $78.9 million |
- Revenue declined 5.7%, principally due to COVID-19-related softness in both end markets. Lower gross profit was largely offset by reduced SG&A and restructuring/acquisition costs; R&D spending increased.
- Operating cash flow rose substantially, helped by lower receivables and inventories and lower income-tax payments. It included a $40.1 million cash benefit from changes in receivables and inventory, partly offset by $14.5 million of lower accounts payable, accrued expenses and other current liabilities.
- At year-end, principal borrowings under the senior credit facilities were $204.8 million; balance-sheet debt, net of unamortized financing costs, was $200.4 million. Revolver availability was $395.2 million. The facilities mature in December 2024.
- Debt covenant measures were within limits: consolidated leverage ratio 1.49 versus a maximum of 3.50; fixed-charge coverage ratio 10.57 versus a minimum of 1.50. Management said liquidity and covenant compliance should be adequate for the next 12 months.
- Current assets were $304.2 million and current liabilities $114.2 million. No cash dividends have been paid; share repurchases were suspended in April 2020.
Fourth-quarter results
For the quarter ended December 31, 2020, revenue was $147.5 million, operating income $17.1 million, net income $12.7 million, and diluted EPS $0.35. Fourth-quarter restructuring and acquisition-related costs included a net credit of $1.8 million.
Segments
| Segment | 2020 revenue | Change vs. 2019 | 2020 operating income |
|---|---|---|---|
| Photonics | $199.6 million | Down 13.4% | $34.0 million |
| Vision | $261.7 million | Down 3.6% | $16.4 million |
| Precision Motion | $129.4 million | Up 4.1% | $31.7 million |
Medical sales represented approximately 56% of revenue, up from 55% in 2019; advanced industrial represented 44%. One medical OEM customer accounted for approximately 11% of 2020 consolidated revenue. International customers generated approximately 62% of revenue.
Material changes and unusual items
- Photonics experienced the steepest revenue decline, reflecting reduced industrial spending, deferred elective procedures and lower diagnostic-testing demand. Vision was affected by fewer minimally invasive procedures. Precision Motion grew, supported by microelectronics demand.
- Consolidated gross margin eased 0.5 percentage point to 41.4%. Photonics margin fell to 44.6% amid lower factory utilization and pandemic-related costs; Precision Motion margin improved to 45.1% on mix and productivity.
- Operating income was broadly stable despite lower sales. Lower SG&A and restructuring/acquisition expenses were partly offset by reduced gross profit and higher R&D spending.
- 2020 share-based compensation expense was $23.1 million, versus $9.3 million in 2019. A one-time employee RSU grant had aggregate grant-date fair value of $14.4 million and vested in February 2021.
- Net income benefited from lower interest expense and a lower tax provision. The effective tax rate was 8.0%, versus 10.9% in 2019, reflecting jurisdictional income mix and tax benefits, including share-based compensation, credits and U.K. patent-box deductions.
- Operating cash flow was substantially above net income, principally because of working-capital releases. Assess whether this level is repeatable.
Outlook, risks and contingencies
- The filing provides no numerical revenue or earnings guidance. Management expected 2021 capital expenditures of approximately $21–$23 million and additional restructuring charges of $4–$5 million over the following 12 months.
- Management described COVID-19 impacts as uncertain: elective-procedure deferrals and customer R&D delays weighed on demand, while shipping constraints raised costs and caused delays. Facilities were operating at year-end and supply-chain disruption had been limited, but further disruption remained possible.
- The company began a 2020 restructuring program focused on reducing operating complexity and improving gross margins; completion was expected in the fourth quarter of 2021. Additional costs and implementation risks remain.
- Key risks include economic and capital-spending cyclicality, customer concentration, single- or limited-source components, international operations and currency exposure, tariffs and trade restrictions, product development and quality, medical-device regulation, cybersecurity/data privacy, acquisition integration, and potential impairment of goodwill and intangible assets. Net goodwill and intangible assets totaled approximately $434.5 million.
- Variable-rate debt creates interest-rate risk: a 100-basis-point increase was estimated to raise annual pretax interest expense by about $2.0 million. Foreign exchange movements also affect results.
- An arbitration claim against a business acquired in 2019 alleges breach of a joint product-development agreement and seeks damages, lost profits and other relief. Novanta considers the claims without merit and recorded no accrual. The filing says other ordinary-course legal matters are not expected to have a material adverse effect, while noting uncertainty.
- There were no goodwill or indefinite-lived intangible impairment charges in 2020. The auditor issued an unqualified opinion and concluded internal control over financial reporting was effective. The audit identified fair-value measurement of acquisition-related contingent consideration as a critical audit matter.
Important facts for investors to verify
- Whether demand recovered in medical procedures and advanced-industrial markets after year-end, and how sales and margins developed by segment.
- Whether 2020 operating cash flow reflected sustainable operating performance or primarily temporary working-capital releases.
- Debt repayments, revolver usage, covenant headroom and the company’s ability to fund planned capital expenditures and restructuring.
- Actual restructuring charges and realized savings, and the recurring impact of elevated share-based compensation.
- Outcome and potential exposure from the arbitration matter, acquisition earn-outs and other contingencies.
- Whether the 11% customer concentration, supply constraints, or changes in foreign exchange, tariffs or regulation materially affect future results.